ATE270305T1 - Peptide des antisekretorischen faktors, welches krankhafte permeabilitätsanderungen reguliert - Google Patents

Peptide des antisekretorischen faktors, welches krankhafte permeabilitätsanderungen reguliert

Info

Publication number
ATE270305T1
ATE270305T1 AT96929619T AT96929619T ATE270305T1 AT E270305 T1 ATE270305 T1 AT E270305T1 AT 96929619 T AT96929619 T AT 96929619T AT 96929619 T AT96929619 T AT 96929619T AT E270305 T1 ATE270305 T1 AT E270305T1
Authority
AT
Austria
Prior art keywords
homologues
fragments
factor
antisecretoric
peptides
Prior art date
Application number
AT96929619T
Other languages
English (en)
Inventor
Ivar Loennroth
Stefan Lange
Eva Johansson
Eva Jennische
Christina Loennroth
Original Assignee
Rural Patent Svenska Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Rural Patent Svenska Ab filed Critical Rural Patent Svenska Ab
Application granted granted Critical
Publication of ATE270305T1 publication Critical patent/ATE270305T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23K—FODDER
    • A23K20/00—Accessory food factors for animal feeding-stuffs
    • A23K20/10—Organic substances
    • A23K20/142—Amino acids; Derivatives thereof
    • A23K20/147—Polymeric derivatives, e.g. peptides or proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12—Antidiarrhoeals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
    • A61P5/40—Mineralocorticosteroids, e.g. aldosterone; Drugs increasing or potentiating the activity of mineralocorticosteroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/12—Antidiuretics, e.g. drugs for diabetes insipidus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Polymers & Plastics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Toxicology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Ophthalmology & Optometry (AREA)
  • Hematology (AREA)
  • Addiction (AREA)
  • Food Science & Technology (AREA)
  • Psychiatry (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Obesity (AREA)
  • Pulmonology (AREA)
  • Immunology (AREA)
  • Animal Husbandry (AREA)
AT96929619T 1995-08-24 1996-08-23 Peptide des antisekretorischen faktors, welches krankhafte permeabilitätsanderungen reguliert ATE270305T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
SE9502936A SE508609C2 (sv) 1995-08-24 1995-08-24 Antisekretorisk faktor - dess aminosyrasekvens, nubleinsyrasekvens och användning
PCT/SE1996/001049 WO1997008202A1 (en) 1995-08-24 1996-08-23 Antisecretory factor peptides regulating pathological permeability changes

Publications (1)

Publication Number Publication Date
ATE270305T1 true ATE270305T1 (de) 2004-07-15

Family

ID=20399269

Family Applications (1)

Application Number Title Priority Date Filing Date
AT96929619T ATE270305T1 (de) 1995-08-24 1996-08-23 Peptide des antisekretorischen faktors, welches krankhafte permeabilitätsanderungen reguliert

Country Status (28)

Country Link
US (2) US6344440B1 (de)
EP (1) EP0851876B1 (de)
JP (2) JP4040679B2 (de)
KR (1) KR100552947B1 (de)
CN (1) CN1171902C (de)
AT (1) ATE270305T1 (de)
AU (1) AU702589B2 (de)
BG (1) BG63209B1 (de)
BR (1) BR9610308A (de)
CA (1) CA2230111C (de)
CZ (1) CZ295444B6 (de)
DE (2) DE69632828T2 (de)
DK (1) DK0851876T3 (de)
EA (1) EA001201B1 (de)
EE (1) EE04501B1 (de)
ES (1) ES2118683T3 (de)
HU (1) HU224971B1 (de)
IL (1) IL123404A (de)
NO (1) NO320560B1 (de)
NZ (2) NZ316647A (de)
PL (1) PL188530B1 (de)
PT (1) PT851876E (de)
RO (1) RO120197B1 (de)
SE (1) SE508609C2 (de)
SI (1) SI0851876T1 (de)
SK (1) SK23698A3 (de)
TR (1) TR199800304T1 (de)
WO (1) WO1997008202A1 (de)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE508609C2 (sv) * 1995-08-24 1998-10-19 Rural Patent Svenska Ab Antisekretorisk faktor - dess aminosyrasekvens, nubleinsyrasekvens och användning
SE9604251L (sv) * 1996-11-20 1997-12-22 Svenska Lantmaennen Riksfoerbu Födoämne som vid förtäring inducerar antisekretoriska proteiner
SE513496C2 (sv) * 1998-12-17 2000-09-18 Rural Patent Svenska Ab NASP-berikad äggula samt dess användning
AU5627000A (en) * 1999-06-21 2001-02-05 Inkine Pharmaceutical Company, Inc. Angiocidin: a CYS-SER-VAL-THR-CYS-GLY specific tumor cell adhesion receptor
GB0322645D0 (en) * 2003-09-26 2003-10-29 Melacure Therapeutics Ab Use of antisecretory factor peptides
KR20090037992A (ko) 2006-04-27 2009-04-17 란트만넨 아스-팍토르 아베 항분비 단백질의 추가적 의학 용도
SG171602A1 (en) * 2006-04-27 2011-06-29 Lantmaennen As Faktor Ab Use of antisecretory factors for treating intraocular hypertension
PL2040734T3 (pl) * 2006-04-27 2012-04-30 Lantmaennen As Faktor Ab Białko przeciwwydzielnicze do zastosowania w leczeniu zespołu przedziału
RU2341981C2 (ru) * 2006-07-03 2008-12-27 Государственное учреждение Всероссийский научно-исследовательский институт пищевых ароматизаторов, кислот и красителей Российской академии сельскохозяйственных наук (ГУ ВНИИПАКК) Комплексная пищевая добавка
US8901083B2 (en) 2008-11-25 2014-12-02 Temple University Administration of angiocidin for the treatment of leukemia
JP5820277B2 (ja) * 2009-02-11 2015-11-24 ラントメネン・アーエス−ファクトール・アーベー 細胞取込を最適化するための抗分泌性因子（ａｆ）の使用
WO2017009004A1 (en) 2015-07-10 2017-01-19 Lantmännen As-Faktor Ab Process for producing egg yolk with high content of af-16
US11407796B2 (en) 2016-07-18 2022-08-09 Lantmännen As-Faktor Ab Antisecretory factor 17
WO2020002464A1 (en) 2018-06-28 2020-01-02 Lantmännen Medical Ab Antisecretory factor for use in treatment and/or prevention of acute respiratory failure
CN112770643A (zh) * 2018-09-28 2021-05-07 兰特门内保健食品公司 包含麦芽化脱壳燕麦的可消耗产品
WO2020065091A1 (en) 2018-09-28 2020-04-02 Lantmännen Functional Foods Ab A consumable product comprising malted wheat
EP4125984A1 (de) 2020-03-26 2023-02-08 Lantmännen Functional Foods AB Verzehrbares produkt mit mälzten getreiden zur förderung der erholung bei körperlicher aktivität
WO2026099453A1 (en) 2024-11-07 2026-05-15 Lantmännen Medical Ab Af-16 or af-17 for acute treatment of brain oedema in patients with traumatic brain injury

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE508609C2 (sv) * 1995-08-24 1998-10-19 Rural Patent Svenska Ab Antisekretorisk faktor - dess aminosyrasekvens, nubleinsyrasekvens och användning

Also Published As

Publication number Publication date
DE851876T1 (de) 1998-11-12
CN1171902C (zh) 2004-10-20
SE9502936L (sv) 1997-02-25
EP0851876A1 (de) 1998-07-08
SI0851876T1 (en) 2004-10-31
DE69632828T2 (de) 2005-07-14
US6344440B1 (en) 2002-02-05
AU6893296A (en) 1997-03-19
AU702589B2 (en) 1999-02-25
EE04501B1 (et) 2005-06-15
PT851876E (pt) 2004-10-29
ES2118683T3 (es) 2004-12-01
SE9502936D0 (sv) 1995-08-24
EE9800055A (et) 1998-08-17
RO120197B1 (ro) 2005-10-28
IL123404A (en) 2005-07-25
EA001201B1 (ru) 2000-12-25
KR100552947B1 (ko) 2006-04-21
JP4040679B2 (ja) 2008-01-30
PL325114A1 (en) 1998-07-06
SE508609C2 (sv) 1998-10-19
NZ337380A (en) 2001-02-23
HU224971B1 (en) 2006-04-28
BR9610308A (pt) 1999-12-21
NO320560B1 (no) 2005-12-19
JP2008043331A (ja) 2008-02-28
JPH11511972A (ja) 1999-10-19
NO980743L (no) 1998-04-16
NO980743D0 (no) 1998-02-23
PL188530B1 (pl) 2005-02-28
BG63209B1 (bg) 2001-06-29
CZ52098A3 (cs) 1998-09-16
DK0851876T3 (da) 2004-10-25
HUP9900137A2 (hu) 1999-04-28
IL123404A0 (en) 1998-09-24
BG102280A (en) 1999-04-30
SK23698A3 (en) 1998-12-02
CA2230111C (en) 2012-10-30
US20020099016A1 (en) 2002-07-25
EP0851876B1 (de) 2004-06-30
CZ295444B6 (cs) 2005-08-17
CN1208420A (zh) 1999-02-17
DE69632828D1 (de) 2004-08-05
KR19990044110A (ko) 1999-06-25
EA199800221A1 (ru) 1998-10-29
NZ316647A (en) 1999-10-28
CA2230111A1 (en) 1997-03-06
WO1997008202A1 (en) 1997-03-06
HK1018468A1 (en) 1999-12-24
TR199800304T1 (xx) 1998-05-21
HUP9900137A3 (en) 1999-11-29
ES2118683T1 (es) 1998-10-01

Similar Documents

Publication Publication Date Title
DE69632828D1 (de) Peptide des antisekretorischen faktors, welches krankhafte permeabilitätsanderungen reguliert
BG104149A (bg) Белтъци, свързващи интерлевкин-18, тяхното получаване и приложение
ES2194911T3 (es) Metodo para evitar la agregacion de proteinas/peptidos cuando tiene lugar su rehidratacion o descongelacion.
PT93910A (pt) Prodesso para a preparacao de uma proteina heterologa mediante secrecao a partir de uma celula
DK1265914T3 (da) WNT-1-relaterede polypeptider og nukleinsyrer, der koder for samme
NO990086L (no) Avkortete, l°selige tumornekrosefaktorreseptorer av type I og type II
PT101297A (pt) Factores mitogenicos gliais, sua preparacao e utilizacao
WO2004003147A3 (en) Cngh0004 polypeptides, antibodies, compositions, methods and uses
ATE368688T1 (de) Peptide, deren herstellung und verwendung zur bindung von immunglobulinen
DK0901526T3 (da) Cortistatin: neuropeptider, sammensætninger og metoder
DE68925275D1 (de) Endotoxin-bindeprotein und dessen verwendung
BG101038A (bg) Супресия на растежа на туморни клетки посредствомсиндекан- 1 ектоучастък
HK1039783A1 (zh) 新的分泌型蛋白和编码它们的多核苷
WO1999033870A3 (en) Human regulatory proteins
SE9602822D0 (sv) New receptor
EP1117682A4 (de) Peptide
ATE550345T1 (de) Sfrp, mit sfrp-interagierende peptidmotive sowie verwendungsverfahren
FI943218A7 (fi) Kaseinomakropeptidin peptidit, mainittujen peptidien vasta-aineet ja k äytöt
WO1999031229A3 (en) Peptides and nucleic acids derived from eisenia foetida and the use thereof
ATE512162T1 (de) Antikörper gegen das p51 protein
SE9604439D0 (sv) New receptor
WO2002097036A3 (en) Compositions and methods for adipose abundant protein
WO2002096355A3 (en) Compositions and methods for adipose abundant protein

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 0851876

Country of ref document: EP